MS4A4A and epilepsy: Looking ahead, research into key genes including MS4A4A, which are associated with microglial states and functions, may pave the way for the development of disease‐modifying anti‐epileptogenic medications (AEMs).[88] Such advancements could extend beyond treating seizures associated with AD, potentially informing the management of epilepsy in a broader context.